Fortress Biotech Inc (FBIO)

0 · Reply

braves1983 May. 11 at 1:49 PM

$FBIO still fucking garbage here. Another loser day and loser week.

0 · Reply

FinSUN May. 8 at 4:13 PM

0 · Reply

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

May 4, 2026, 8:30 AM EDT - 8 days ago

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Apr 21, 2026, 8:30 AM EDT - 21 days ago

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Mar 31, 2026, 4:05 PM EDT - 6 weeks ago

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Mar 30, 2026, 4:05 PM EDT - 6 weeks ago

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Mar 25, 2026, 4:01 PM EDT - 6 weeks ago

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Mar 18, 2026, 8:30 AM EDT - 7 weeks ago

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Feb 23, 2026, 9:24 AM EST - 2 months ago

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

2026-02-23T13:53:18.000Z - 2 months ago

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

Feb 23, 2026, 8:30 AM EST - 2 months ago

Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Feb 23, 2026, 8:00 AM EST - 2 months ago

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

2026-01-13T12:50:22.000Z - 4 months ago

Fortress Biotech, Cyprium announce FDA approval of ZYCUBO

Jan 13, 2026, 7:45 AM EST - 4 months ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

2025-12-16T11:11:34.000Z - 5 months ago

Fortress Biotech files to sell 600,000 shares of common stock for holders

2025-12-15T13:10:58.000Z - 5 months ago

Fortress Biotech, Cyprium announce FDA acceptance of CUTX-101 NDA resubmission

Dec 15, 2025, 8:00 AM EST - 5 months ago

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Dec 10, 2025, 8:30 AM EST - 5 months ago

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

2025-11-19T12:15:57.000Z - 6 months ago

Fortress Biotech price target raised to $4.50 from $4 at Alliance Global

2025-11-14T13:40:48.000Z - 6 months ago

Fortress Biotech reports Q3 EPS 11c vs (76c) last year

Nov 14, 2025, 8:30 AM EST - 6 months ago

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 12, 2025, 4:30 PM EST - 6 months ago

Fortress Biotech Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:01 PM EST - 6 months ago

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 6, 2025, 7:00 AM EST - 6 months ago

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

AXSM

Nov 5, 2025, 8:30 AM EST - 6 months ago

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Oct 24, 2025, 8:30 AM EDT - 7 months ago

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

2025-10-21T12:35:27.000Z - 7 months ago

Fortress subsidiary announces Crystalys dosed patient in study of dotinurad

Oct 21, 2025, 8:30 AM EDT - 7 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout

Oct 8, 2025, 8:30 AM EDT - 7 months ago

Journey Medical Corporation to Participate in October 2025 Investor Conferences

Oct 1, 2025, 3:45 PM EDT - 7 months ago

Fortress Biotech Investigated by the Portnoy Law Firm

2025-10-01T13:07:24.000Z - 7 months ago

Why Is Fortress Biotech Stock (FBIO) Down 30% Today?

2025-10-01T12:30:16.000Z - 7 months ago

Fortress Biotech, Urica announces Crystalys’ $205M Series A financing

2025-10-01T12:11:28.000Z - 8 months ago

Fortress Biotech, Cyprium receive CRL related to NDA for CUTX-101

Oct 1, 2025, 8:05 AM EDT - 8 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

Oct 1, 2025, 8:00 AM EDT - 8 months ago

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

Sep 3, 2025, 8:30 AM EDT - 8 months ago

Journey Medical Corporation to Participate in September 2025 Investor Conferences

Sep 2, 2025, 8:30 AM EDT - 9 months ago

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-21T10:20:36.000Z - 9 months ago

Fortress Biotech price target lowered to $17 from $26 at H.C. Wainwright

2025-08-19T12:15:37.000Z - 9 months ago

Fortress Biotech price target lowered to $12 from $15 at Roth Capital

Aug 18, 2025, 8:30 AM EDT - 9 months ago

Journey Medical Corporation to Present at the Emerging Growth Conference

Aug 14, 2025, 4:05 PM EDT - 9 months ago

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 7, 2025, 8:30 AM EDT - 9 months ago

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

Aug 5, 2025, 4:01 PM EDT - 10 months ago

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

Jul 14, 2025, 8:30 AM EDT - 10 months ago

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Jun 24, 2025, 8:30 AM EDT - 11 months ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

Jun 20, 2025, 8:30 AM EDT - 11 months ago

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

Jun 17, 2025, 10:00 AM EDT - 11 months ago

Fortress Biotech Transcript: AGM 2025

Jun 9, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

May 30, 2025, 10:47 AM EDT - 1 year ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

May 15, 2025, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 14, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 13, 2025, 4:15 PM EDT - 1 year ago

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

CKPT

2025-05-08T15:45:41.000Z - 1 year ago

Fortress Biotech management to meet virtually with Roth MKM

May 7, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

Apr 1, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

CKPT

Mar 26, 2025, 4:30 PM EDT - 1 year ago

Fortress Biotech Earnings Call Transcript: Q4 2024

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

2025-03-17T13:07:15.000Z - 1 year ago

Fortress Biotech, Partex enter collaboration for asset identification

2025-03-17T13:00:50.000Z - 1 year ago

Fortress Biotech, Partex enter collaboration for asset identification, evaluatio

Mar 17, 2025, 8:55 AM EDT - 1 year ago

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

Mar 12, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

Nivw May. 12 at 7:06 PM

$FBIO lol this was a bad trade, what a garbage stock. Luckily 170 shares only did not trust it with more and don't want to average down. Let's see what earnings bring...

2 · Reply

FinSUN May. 12 at 2:22 PM

$FBIO no worries, the 2.2 double bottom feeders will try to keep it afloat 😏

1 · Reply

braves1983 May. 12 at 1:47 PM

$FBIO down 28 cents for no reason. No news. Nothing. Just pathetic here.

0 · Reply

wolfman1271 May. 11 at 8:47 PM

$FBIO Down during the day, up after hours. Is this the shorts doing this or what?

1 · Reply

FinSUN May. 11 at 7:17 PM

$FBIO funny how people on this thread continue to ignore my signals and pat themselves on their bagholders' shoulders...

0 · Reply

braves1983 May. 11 at 6:40 PM

$FBIO so much for 2.50. Literally back where it was two weeks ago. Fucking horseshit. Enjoyed 20 cents and now it’s all gone.

0 · Reply

unmvar May. 11 at 6:24 PM

$FBIO is there any chance of this getting to $3.10 in the next few days?? i have been waiting on this to pop ever since the sale of PRV and no luck yet...not looking good at all...

2 · Reply

FinSUN May. 11 at 1:53 PM

0 · Reply

braves1983 May. 11 at 1:49 PM

$FBIO still fucking garbage here. Another loser day and loser week.

0 · Reply

FinSUN May. 8 at 4:13 PM

0 · Reply

wolfman1271 May. 8 at 3:37 PM

$FBIO Could a reverse split be in play?

3 · Reply

FinSUN May. 8 at 9:36 AM

$FBIO the stock is still 33% higher YoY. Given the governance, the debt, the unresolved dividends payment and the total disaster of many subsidiaries like $MBIO and $ATXI plus the disappointing revenue of $DERM , not to mention the ongoing dilution with B. $RILY as ATM agent, I consider this still overpriced.

1 · Reply

FinSUN May. 7 at 9:27 PM

$FBIO now, thanks to this breather bounce, we can move this back to $2, $FBIOP to $11.

3 · Reply

makrodimutross May. 7 at 8:11 PM

$FBIO marginal bounceback with XBI, but weak into the close. Fragile.

0 · Reply

braves1983 May. 7 at 6:11 PM

$FBIO and just like that 4 Green Day’s mean nothing. Takes one day to wipe it out. Awesome

1 · Reply

FinSUN May. 7 at 5:04 PM